lapatinib / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 236 Diseases   42 Trials   42 Trials   3908 News 


«12...3132333435363738394041...4849»
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Biomarker, Enrollment change, Trial completion date, Trial primary completion date:  Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) -  Oct 25, 2018   
    P2,  N=225, Active, not recruiting, 
    Further studies are warranted to investigate how to use these biomarkers to identify upfront patients who may respond to anti-HER2 alone, without chemotherapy. N=42 --> 225 | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Nov 2018
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity. (Pubmed Central) -  Sep 29, 2018   
    More importantly, the patient had one year of disease control without deterioration in her ejection fraction. We discussed the management of recurrent HER2+ breast cancer with chest wall disease and the choice of anti-HER2 therapy in patients with a history of transtuzumab-induced cardiac dysfunction.
  • ||||||||||  lapatinib / Generic mfg., temozolomide / Generic mfg.
    Trial completion, Trial primary completion date:  Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma (clinicaltrials.gov) -  Sep 28, 2018   
    P2,  N=58, Completed, 
    We discussed the management of recurrent HER2+ breast cancer with chest wall disease and the choice of anti-HER2 therapy in patients with a history of transtuzumab-induced cardiac dysfunction. Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jul 2018
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion date, Trial primary completion date:  A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer (clinicaltrials.gov) -  Sep 27, 2018   
    P2,  N=159, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jul 2018 Trial completion date: Jun 2018 --> Dec 2020 | Trial primary completion date: Apr 2018 --> Apr 2020
  • ||||||||||  lapatinib / Generic mfg.
    Phase classification, Trial primary completion date, Surgery:  Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (clinicaltrials.gov) -  Sep 21, 2018   
    P1,  N=33, Recruiting, 
    Trial completion date: Jun 2018 --> Dec 2020 | Trial primary completion date: Apr 2018 --> Apr 2020 Phase classification: P=N/A --> P1 | Trial primary completion date: Jun 2018 --> Dec 2018
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Enrollment closed, Trial primary completion date:  EPHOS-B: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer (clinicaltrials.gov) -  Sep 17, 2018   
    P3,  N=257, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2017
  • ||||||||||  lapatinib / Generic mfg., Avastin (bevacizumab) / Roche
    Clinical, Journal:  Adjuvant treatments for ependymomas. (Pubmed Central) -  Aug 8, 2018   
    Targeted agents such as bevacizumab and lapatinib do not have a role in adjuvant therapy for ependymomas but are being explored for recurrent disease. This review discusses adjuvant therapy in both adult and child populations.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date:  TEAL: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel (clinicaltrials.gov) -  Jul 26, 2018   
    P2,  N=24, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> May 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2017 --> Jun 2019 | Trial primary completion date: Jun 2017 --> Jan 2019
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    Enrollment closed, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  STELA: T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov) -  Jul 26, 2018   
    P1,  N=24, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2017 --> Jun 2019 | Trial primary completion date: Jun 2017 --> Jan 2019 Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=45 --> 24 | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Combination therapy, Metastases:  Lapatinib and Bevacizumab for Metastatic Breast Cancer (clinicaltrials.gov) -  Jul 24, 2018   
    P2,  N=52, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=45 --> 24 | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018 Trial completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Journal:  HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. (Pubmed Central) -  Jun 22, 2018   
    HER2L755S-specific siRNA knockdown reversed the resistance in BT474/AZ-LR and BT474/ATCC-LTR lines. The HER1/2 irreversible inhibitors afatinib and neratinib substantially inhibited both resistant cell growth and the HER2 and downstream AKT/MAPK signaling driven by HER2L755S in vitro and in vivo HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to L-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.
  • ||||||||||  lapatinib / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
    Trial completion date, Surgery:  Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery (clinicaltrials.gov) -  Jun 3, 2018   
    P2,  N=40, Active, not recruiting, 
    Mature OS results are still expected for the Aphinity trial and for the sequential use of trastuzumab followed by neratinib, the treatment that showed the best performance in terms of DFS in our analysis. Trial completion date: Aug 2019 --> Nov 2031
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion, Trial completion date, Trial primary completion date:  Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone (clinicaltrials.gov) -  Jun 2, 2018   
    P3,  N=280, Completed, 
    Trial completion date: Aug 2019 --> Nov 2031 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2018 | Trial primary completion date: Dec 2019 --> Mar 2018
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion, Trial completion date:  Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer (clinicaltrials.gov) -  May 1, 2018   
    P2,  N=244, Completed, 
    Trial completion date: Mar 2018 --> Mar 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion date, Trial primary completion date:  Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer (clinicaltrials.gov) -  Apr 18, 2018   
    P2,  N=55, Active, not recruiting, 
    Trial completion date: Feb 2018 --> Jun 2019 | Trial primary completion date: Feb 2018 --> Jun 2018 Trial completion date: Apr 2018 --> Apr 2019 | Trial primary completion date: Apr 2018 --> Apr 2019
  • ||||||||||  lapatinib / Generic mfg., capecitabine / Generic mfg.
    Trial completion date, Metastases:  Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China (clinicaltrials.gov) -  Mar 30, 2018   
    P3,  N=52, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=40 --> 10 | Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Dec 2016 --> Dec 2018
  • ||||||||||  lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    Trial completion, Trial completion date, Metastases:  Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC (clinicaltrials.gov) -  Mar 7, 2018   
    P2,  N=60, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion date, Trial primary completion date:  Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer (clinicaltrials.gov) -  Feb 23, 2018   
    P2,  N=116, Active, not recruiting, 
    Enrichment of CD44v-positive tumor cells after dual anti-HER2 therapy alone may predict poor response to dual anti-HER2 therapy plus chemotherapy. Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial primary completion date:  Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer (clinicaltrials.gov) -  Feb 22, 2018   
    P2,  N=244, Active, not recruiting, 
    Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Dec 2018 --> Sep 2007
  • ||||||||||  lapatinib / Generic mfg.
    Clinical, Journal:  Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. (Pubmed Central) -  Feb 10, 2018   
    The addition of lapatinib to GC as neoadjuvant therapy for MIBC was limited by excessive treatment-related toxicity. These findings highlight the importance of thorough dose-escalation investigation of combination therapies prior to evaluation in the neoadjuvant setting, as well as the limitations of determination of maximum tolerated dose for novel targeted combination regimens.